cytarabine and ly2603618

cytarabine has been researched along with ly2603618 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fang, S; Gao, A; Hu, X; Hu, Y; Jiang, K; Jin, T; Li, J; Liu, T; Song, P; Tong, L; Wang, P; Xu, L; Zhou, Y	1

Other Studies

1 other study(ies) available for cytarabine and ly2603618

Article	Year
Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies. European journal of medicinal chemistry, 2019, Jul-01, Volume: 173 Topics: Checkpoint Kinase 1; Dose-Response Relationship, Drug; Drug Discovery; Hematologic Neoplasms; Humans; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship	2019

Article

Year

Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies.

European journal of medicinal chemistry, 2019, Jul-01, Volume: 173

Topics: Checkpoint Kinase 1; Dose-Response Relationship, Drug; Drug Discovery; Hematologic Neoplasms; Humans; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship

2019